GlassScriptPhysician profile
Jason Ryan Mammino
NPI 1548757073
$8,795.63
in general payments reported to CMS, 2019-2025
29 companies · $3,764 in 2025
The $3,764 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $399 · 2021: $389 · 2022: $279 · 2023: $1,470 · 2024: $2,370 · 2025: $3,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,068 · Education: $535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,068.03 |
| Education | $535.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,274.71 | 2020-2025 | |
| Janssen Biotech, INC. | $925.02 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| E.R. Squibb & Sons, L.L.C. | $669.69 | 2022-2025 | Sotyktu |
| Ucb, INC. | $664.28 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $441.58 | 2022-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $390.53 | 2020-2025 | Dupixent |
| Galderma Laboratories, L.P. | $356.34 | 2022-2025 | Nemluvio, Dysport, Aklief |
| Sun Pharmaceutical Industries INC. | $318.50 | 2023-2025 | Ilumya, Odomzo, Blu-U |
| Incyte Corporation | $285.98 | 2021-2025 | Opzelura |
| Genzyme Corporation | $283.54 | 2021-2025 | |
| Dermavant Sciences, INC. | $260.87 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $244.08 | 2024-2025 | |
| Pfizer INC. | $232.06 | 2024-2025 | |
| Leo Pharma INC. | $193.65 | 2023-2025 | Adbry, Anzupgo |
| Convatec INC. | $180.22 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $179.07 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $172.05 | 2024-2025 | Zoryve |
| Organon LLC | $167.10 | 2024-2025 | Vtama |
| Genentech USA, INC. | $151.67 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $115.66 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $65.44 | 2021 | |
| Almirall LLC | $54.55 | 2021-2025 | Seysara, Klisyri |
| Sandoz INC. | $35.36 | 2024 | Hyrimoz |
| Mayne Pharma Commercial LLC | $30.35 | 2022 | |
| Biofrontera INC. | $28.48 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Dermira, INC. | $20.99 | 2021 | |
| Organogenesis INC. | $19.97 | 2023 | Puraply |
| Paratek Pharmaceuticals, INC. | $17.09 | 2023 | Nuzyra |
| Verrica Pharmaceuticals INC. | $16.80 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Mammino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.